Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
7.39B
Market cap7.39B
Price-Earnings ratio
-12.80
Price-Earnings ratio-12.80
Dividend yield
Dividend yield
Average volume
5.23M
Average volume5.23M
High today
$47.44
High today$47.44
Low today
$44.29
Low today$44.29
Open price
$46.66
Open price$46.66
Volume
7.28M
Volume7.28M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$44.27
52 Week low$44.27

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $44.92, giving the company a market capitalization of 7.39B. It carries a P/E multiple of -12.80.

As of 2026-09-20, Ionis Pharmaceuticals(IONS) stock has fluctuated between $44.29 and $47.44. The current price stands at $44.92, placing the stock +1.4% above today's low and -5.3% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 7.28M, against a daily average of 5.23M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $44.27 at its lowest and $86.74 at its peak.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $44.27 at its lowest and $86.74 at its peak.

IONS News

Simply Wall St 6h
Ionis Pharmaceuticals Could Be 50% Undervalued As Pelacarsen Setback Resets Sentiment

Ionis Pharmaceuticals (IONS) is back in the spotlight after partner Novartis reported that the pivotal Phase 3 Lp(a)HORIZON trial of pelacarsen missed its cardi...

Ionis Pharmaceuticals Could Be 50% Undervalued As Pelacarsen Setback Resets Sentiment
Simply Wall St 1d
Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Stock

Novartis reported that pelacarsen, co developed with Ionis Pharmaceuticals to lower lipoprotein(a), reduced Lp(a) levels in a large Phase 3 trial but did not cu...

Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Stock
Simply Wall St 3d
Ionis Stock Looks Fully Valued As A Phase 3 Trial Miss Lands

has seen its share price fall sharply this year, which puts a spotlight on whether the current market value lines up with the sales it is generating. After a fr...

Ionis Stock Looks Fully Valued As A Phase 3 Trial Miss Lands

Analyst ratings

81%

of 27 ratings
Buy
81.5%
Hold
18.5%
Sell
0%

More IONS News

TipRanks 5d
Ionis Pharmaceuticals price target lowered to $80 from $89 at Guggenheim

Guggenheim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $89 and keeps a Buy rating on the shares. The firm’s “quick poll” of 30 U...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.